Pharmacy benefit managers retain billions through spread pricing that employers and patients cannot see or audit

Pharmacy benefit managers (PBMs) reimburse pharmacies at one rate for dispensing a drug, then charge the health plan a higher rate, pocketing the spread — a practice that generated $1.4 billion for the three largest PBMs between 2017 and 2021 according to the FTC, and the true figure is believed to be far higher because PBM contracts prohibit disclosure. So what? Self-insured employers (who cover 65% of workers with employer-sponsored insurance) cannot determine whether their PBM is acting in their financial interest or extracting hidden fees, because contract terms include gag clauses and anti-transparency provisions. So what? Costs on specialty medications — which now represent over 50% of total drug spending — can vary by tens of thousands of dollars depending on the PBM involved, meaning a patient's employer might be overpaying by $20,000+ per year per specialty patient without knowing it. So what? These hidden costs flow directly into higher premiums, higher deductibles, and higher copays for employees, who may then skip medications they cannot afford — the #1 cause of preventable hospital admissions for chronic conditions like diabetes and heart failure. So what? Independent pharmacies, which serve as the only pharmacy option in many rural communities, are reimbursed below acquisition cost by PBMs and forced to close, creating pharmacy deserts. This persists structurally because the PBM market is dominated by three companies (CVS Caremark, Express Scripts, OptumRx) that control ~80% of the market, vertically integrated with insurers and pharmacies, creating conflicts of interest that current antitrust enforcement has not addressed despite bipartisan congressional interest.